91,579 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Acquired by Norges Bank

Norges Bank bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 91,579 shares of the company’s stock, valued at approximately $1,315,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Verition Fund Management LLC increased its position in shares of 10x Genomics by 26.3% during the 3rd quarter. Verition Fund Management LLC now owns 13,860 shares of the company’s stock worth $313,000 after purchasing an additional 2,890 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of 10x Genomics during the third quarter valued at about $430,000. Stifel Financial Corp raised its stake in shares of 10x Genomics by 56.2% in the 3rd quarter. Stifel Financial Corp now owns 16,369 shares of the company’s stock valued at $370,000 after acquiring an additional 5,890 shares during the period. State Street Corp lifted its holdings in shares of 10x Genomics by 7.1% in the 3rd quarter. State Street Corp now owns 1,750,643 shares of the company’s stock worth $39,530,000 after acquiring an additional 116,534 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of 10x Genomics in the 3rd quarter worth approximately $402,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Trading Up 4.0 %

Shares of NASDAQ:TXG opened at $8.01 on Friday. The firm has a 50 day simple moving average of $10.44 and a 200-day simple moving average of $13.96. 10x Genomics, Inc. has a twelve month low of $6.78 and a twelve month high of $36.15. The company has a market capitalization of $979.64 million, a PE ratio of -5.27 and a beta of 2.01.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of research analyst reports. Stifel Nicolaus cut their target price on 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Leerink Partners downgraded 10x Genomics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $25.00 to $12.00 in a research report on Thursday, February 13th. Leerink Partnrs lowered shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 13th. Finally, Citigroup decreased their price target on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $19.79.

Insider Activity at 10x Genomics

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the purchase, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now directly owns 879,482 shares in the company, valued at $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.